| TP53 | KRAS |
---|---|---|
Rekhtman et al. (LCC) [6] | – | 5 / 20 (25%) |
Pelosi et al. (LCC) [17] | 12 / 20 (60%) | 4 / 20 (20%) |
Harms et al. (LCC) [3] | 11 / 19 (58%) | 6 / 19 (32%) |
Liu et al. (LCC) [12] | 4 / 8 (50%) | 2 / 8 (25%) |
Zhou et al. (LCC) [18] | 3 / 5 (60%) | – |
Our data (LCC) | 4 / 7 (57.1%) | 3 / 7 (42.8%) |
Our data (LCNEC-null) | 11 / 11 (100%) | 0 / 11 (0%) |
Our data (LCNEC) | 12 / 13 (92.3%) | 1 / 13 (7.7%) |
Zhou et al. (LCNEC) [18] | 12 / 14 (86%) | – |
Karlsson et al. (LCNEC) [19] | 28 / 32 (87.5%) | 2 / 32 (6%) |
Naidoo et al. (LCNEC) [11] | – | 4 / 17 (24%) |
Miyoshi et al. (LCNEC) [20] | 55 / 78 (71%) | 5 / 78 (6%) |
George et al. (LCNEC) [21] | 55 / 60 (92%) | 6 / 60 (10%) |
Rekhtman et al. (LCNEC) [22] | 35 / 45 (78%) | 10 / 45 (22%) |